[go: up one dir, main page]

WO2003000274A3 - Nouvelle preparation - Google Patents

Nouvelle preparation Download PDF

Info

Publication number
WO2003000274A3
WO2003000274A3 PCT/GB2002/002879 GB0202879W WO03000274A3 WO 2003000274 A3 WO2003000274 A3 WO 2003000274A3 GB 0202879 W GB0202879 W GB 0202879W WO 03000274 A3 WO03000274 A3 WO 03000274A3
Authority
WO
WIPO (PCT)
Prior art keywords
bacteriophage
bacteriophage preparation
pathogen
cell
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/002879
Other languages
English (en)
Other versions
WO2003000274A2 (fr
Inventor
David West
Vladimir Di Pasechnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHAGE GENOMICS Inc
POLYANSKAYA NATASHA HF
Original Assignee
PHAGE GENOMICS Inc
POLYANSKAYA NATASHA HF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHAGE GENOMICS Inc, POLYANSKAYA NATASHA HF filed Critical PHAGE GENOMICS Inc
Priority to AU2002314331A priority Critical patent/AU2002314331A1/en
Publication of WO2003000274A2 publication Critical patent/WO2003000274A2/fr
Anticipated expiration legal-status Critical
Publication of WO2003000274A3 publication Critical patent/WO2003000274A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une préparation bactériophage comprenant un bactériophage qui est conçu pour pénétrer dans une cellule eucaryote et/ou un compartiment cellulaire eucaryote, ledit bactériophage ayant une action lytique sur au moins une souche de la bactérie pathogène qui est susceptible d'infecter ladite cellule ou ledit compartiment cellulaire, ledit bactériophage fusionnant à, ou étant lié à, ou étant conçu pour exprimer un fragment d'annihilation qui est capable de provoquer ou de stimuler la mort ou l'inactivation de ladite cellule en la présence d'au moins un agent pathogène spécifique, de sorte que ladite préparation bactériophage est capable de provoquer ou de stimuler la mort ou l'inactivation de cellules qui sont infectées par ledit agent pathogène. L'invention a également pour objet une composition pharmaceutique comprenant une préparation bactériophage de ce type, formulée pour être administrée à un patient qui en a besoin, un procédé permettant de produire la mort ou l'inactivation d'une cellule infectée par un agent pathogène par administration au patient d'une préparation bactériophage de ce type, et l'utilisation d'une préparation bactériophage de ce type pour produire une composition pharmaceutique, éventuellement utilisée dans le cadre du traitement et/ou de la prévention d'une maladie qui est médiée ou caractérisée par l'infection intracellulaire par un agent pathogène, comprenant en particulier la tuberculose, le SIDA, l'infection par le VIH, et la malaria.
PCT/GB2002/002879 2001-06-22 2002-06-21 Nouvelle preparation Ceased WO2003000274A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002314331A AU2002314331A1 (en) 2001-06-22 2002-06-21 Bacteriophage preparation for the treatment of intracellular bacterial infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0115385.7A GB0115385D0 (en) 2001-06-22 2001-06-22 Novel preparation
GB0115385.7 2001-06-22

Publications (2)

Publication Number Publication Date
WO2003000274A2 WO2003000274A2 (fr) 2003-01-03
WO2003000274A3 true WO2003000274A3 (fr) 2004-03-18

Family

ID=9917220

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/002879 Ceased WO2003000274A2 (fr) 2001-06-22 2002-06-21 Nouvelle preparation

Country Status (3)

Country Link
AU (1) AU2002314331A1 (fr)
GB (1) GB0115385D0 (fr)
WO (1) WO2003000274A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108126190B (zh) * 2017-11-02 2021-01-26 重庆医科大学附属第一医院 分枝杆菌噬菌体裂解酶Lysin-Guo1的制备与应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0320838D0 (en) 2003-09-05 2003-10-08 Univ Nottingham Disinfection of foodstuffs
TW200934871A (en) 2007-10-01 2009-08-16 Omnilytics Inc Methods for drying bacteriophage and bacteriophage-containing compositions, the resulting dry compositions, and methods of use
GB201217097D0 (en) * 2012-09-25 2012-11-07 Fixed Phage Ltd Treatment of bacterial infection
PL232951B1 (pl) 2013-06-03 2019-08-30 Inst Immunologii I Terapii Doswiadczalnej Im Ludwika Hirszfelda Polskiej Akademii Nauk Zastosowanie bakteriofaga T4
US20200078425A1 (en) * 2017-03-14 2020-03-12 Brigham Young University Methods and Compositions for Treating Obesity, Inflammation, or Metabolic Disorders with Bacteriophages
US11986502B2 (en) 2018-05-23 2024-05-21 Optium, LLC Bacteriophage compositions and kits and related methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005344A1 (fr) * 1996-08-05 1998-02-12 Brigham And Women's Hospital, Inc. Therapie genique a mediation par bacteriophages
WO1999010485A1 (fr) * 1997-08-29 1999-03-04 Selective Genetics, Inc. Procedes utilisant une presentation de phage pour selectionner des ligands internalisants en vue d'une administration de gene
WO2000061190A2 (fr) * 1999-04-09 2000-10-19 Microbiological Research Authority Traitement d'infections intracellulaires
WO2001015511A2 (fr) * 1999-09-01 2001-03-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identification de peptides facilitant l'absorption et le transport cytoplasmique et/ou nucleaire de proteines, d'adn et de virus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005344A1 (fr) * 1996-08-05 1998-02-12 Brigham And Women's Hospital, Inc. Therapie genique a mediation par bacteriophages
WO1999010485A1 (fr) * 1997-08-29 1999-03-04 Selective Genetics, Inc. Procedes utilisant une presentation de phage pour selectionner des ligands internalisants en vue d'une administration de gene
WO2000061190A2 (fr) * 1999-04-09 2000-10-19 Microbiological Research Authority Traitement d'infections intracellulaires
WO2001015511A2 (fr) * 1999-09-01 2001-03-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identification de peptides facilitant l'absorption et le transport cytoplasmique et/ou nucleaire de proteines, d'adn et de virus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
H.M. ELLERBY ET AL.: "Anti-cancer activity of targeted pro-apoptotic peptides", NATURE MEDICINE, vol. 5, no. 9, 1999, pages 1032 - 1038, XP002186751 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108126190B (zh) * 2017-11-02 2021-01-26 重庆医科大学附属第一医院 分枝杆菌噬菌体裂解酶Lysin-Guo1的制备与应用

Also Published As

Publication number Publication date
GB0115385D0 (en) 2001-08-15
AU2002314331A1 (en) 2003-01-08
WO2003000274A2 (fr) 2003-01-03

Similar Documents

Publication Publication Date Title
ATE295180T1 (de) Zubereitung zur immunisierung gegen den aids- virus
MX2010001379A (es) Vectores de tranferencia de gen lentiviral y sus aplicaciones medicinales.
WO2002085248A3 (fr) Prostanoides pouvant augmenter la penetration de medicaments oculaires
AU5821000A (en) Vaccine
EP4321217A3 (fr) Composés de pyridotriazine substitués et leurs utilisations
WO2003000274A3 (fr) Nouvelle preparation
CY1105408T1 (el) Χρησιμοποιηση στελεχων του ιου parapox ovis για την παρασκευη αντιικων φαρμακων και φαρμακων κατα του καρκινου
KR100272743B1 (ko) Hiv 감염의 치료에 유용한 미코박테리움 바케로부터의 항원물질
AU2002354900A1 (en) Methods of polyvalent bacteriophage preparation for the treatment of bacterial infections
JP2006507295A5 (fr)
WO2003009859A1 (fr) Immunotherapie pour humains
WO2004000207A3 (fr) Antibiotique bactéricide à bactériophages et utilisations de ce dernier
WO2004112832A3 (fr) Compositions immunogenes comportant des antigenes gonococciques multiples
WO2004033479A3 (fr) Les retrocyclines, des peptides antiviraux et antimicrobiens
EP1546415A4 (fr) Anticorps anti-tsg101 et leurs utilisations pour traiter des infections virales
WO2006045616A3 (fr) $g(b)-l-n4-hydroxycytosine desoxynucleosides et leur utilisation comme agents pharmaceutiques dans la prophylaxie ou le traitement de maladies virales
PL1765370T3 (pl) Parapoksywirusy w kombinacji z innymi czynnikami przeciwwirusowymi do leczenia HIV/AIDS
Mikić The 2015 Nobel Prize laureates in physiology or medicine
WO2002007760A3 (fr) Agent therapeutique
WO2001054652A3 (fr) Procede permettant d'induire une autovaccination contre le virus de l'immunodeficience humaine au moyen d'interruptions structurees du traitement
Gilks Man, monkeys and malaria
WO2004066954A3 (fr) Composition therapeutique destinee au traitement du virus hiv-1 et hiv-2
ATE425986T1 (de) Antibakterielle behandlungsmethoden
DOP2001000211A (es) Uso de cepas de parapoxvirus ovis para la fabricación de medicamentos antivirales y medicamentos contra el cancer
Hamilton et al. Man, monkeys and malaria

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC, FORM 1205A, DATE OF NOTIFICATION 28.10.2004.

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP